Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Excel Crop Care up 10% in Q2

Indian agrochemical company Excel Crop Care's (Mumbai) revenues rose by 9.7% to Rs 2,948.9 million ($47.9 million at the current rate) in its second quarter ended September 30th 2014. Net profit went up by almost a quarter (23.1%) to Rs 286 million ($4.7 million). Buoyed by the 26.9% growth during the first quarter, six-month sales were up by 18.5% to Rs 6,198.6 million ($100.8 million). Net profit for the first half was up by 44.1% to Rs 617.8 million. The company notes that production and the domestic sale of the insecticide/acaricide, endosulfan, remains suspended following an Indian Supreme Court ban in 2011. Out of the provision of Rs 69.9 million ($1.1 million) for endosulfan-related inventory items carried forward at the end of the fiscal year ended March 31st 2014, an amount of Rs 45 million ($700,000) was written back during the first two quarters and the balance of Rs 24.9 million ($400,000) is being carried forward.

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AG002755

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel